ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In the final segment of her post-SCOPE X interview, Liz Beatty made the case for moving beyond trial-by-trial planning toward cross-asset site partnerships. Sites are three times more likely to share patient data when sponsors commit to sustained, multi-study relationships rather than transactional single-trial engagements.
• In a new contributed article, the vaccine trial industry is standardizing eCOA design through reusable component libraries and templates, reducing build times by 50% and enabling deployment in two to four weeks. A major pharmaceutical company standardizing across eight Phase III vaccine trials with 50,000 participants found 80% of data fields identical across studies, enabling rapid reconfiguration instead of reinvention.
• In a Pharmaceutical Executive article, real-world data is revealing critical gaps in ovarian cancer care, including racial disparities where Black women present at Stage III/IV 77% of the time versus 70% for White women. RWD linked with genomic data and AI tools is enabling smarter trial design, identifying underrepresented populations, and informing treatment strategies in diverse patient populations.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.